Danny Yeung, CEO of Prenetics, discusses the evolution of consumer genetic testing and the company’s growth strategy.
On Market Evolution
Q: How has consumer genetic testing evolved?
Danny Yeung: The market has matured significantly over the past several years. Early adoption was driven largely by curiosity about ancestry, but we are now seeing increased interest in actionable health insights. Consumers want to understand their genetic predispositions and take preventive action.
This shift plays to our strengths. Prenetics has always focused on health-related genetic testing, and our platform delivers clinically meaningful insights that can guide healthcare decisions.
On Product Strategy
Q: What products are you focused on?
Danny Yeung: We continue to expand our product portfolio across preventive health, with tests covering cancer risk, cardiovascular health, pharmacogenomics, and wellness optimization. Our digital health tools help consumers understand and act on their genetic information.
We are also developing B2B offerings for healthcare providers and employers who want to offer genetic testing as part of wellness programs.
On Growth Markets
Q: Where do you see the biggest growth opportunities?
Danny Yeung: Asia represents a significant opportunity for genetic testing. The region has large populations, rising healthcare spending, and increasing awareness of preventive health. Our presence in Hong Kong and Southeast Asia positions us well to capture this growth.
We are also seeing strong traction in the Middle East and are exploring opportunities in other high-growth markets.
On Technology
Q: How are you leveraging technology?
Danny Yeung: Technology is core to everything we do. Our platform uses advanced analytics and AI to interpret genetic data and deliver personalized insights. We are continuously improving our algorithms to provide more accurate and actionable information.